Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV

Paolo Palma, Maria Luisa Romiti, Caterina Cancrini, Simone Pensieroso, Carla Montesano, Marilina B. Santucci, Stefania Bernardi, Alessandra M. Martino, Paolo Rossi, Guido Castelli-Gattinara

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To assess the virological, immunological and metabolic effects of switching from an efficacious first-line protease inhibitor (PI)-based HAART to a simplified triple nucleoside reverse transcriptase inhibitor (NRTI) regimen in children vertically infected with HIV. DESIGN: Prospective, open-label, before-after study of 20 vertically infected children with at least 12 consecutive months of undetectable viral load under a PI-based HAART and no previous history of NRTI treatment. METHODS: At study entry, HAART was shifted to a triple-NRTI combination. RESULTS: The children were aged 2 to 18 years (median, 7.9) and were followed for 96 weeks. All were receiving a PI-based regimen for an average duration of 4 years before enrollment. At study entry, 12 patients (60%) switched to abacavir, 5 (25%) to lamivudine; 2 (10%) to zidovudine and 2 to didanosine (10%). All but one patient maintained plasma HIV RNA <50 copies/ml during the entire follow-up. No immunological failure was observed at week 96. A trend of normalization (P <0.001) of T cell receptor Vβ families of the CD8 cell subset was detected in 19/20 (95%), with an increased HIV-specific CD8 T cell response (P <0.01) in 17/20 (85%). Dyslipidaemia significantly improved during the follow up (P <0.001). No new cases of lipodystrophy were detected. CONCLUSIONS: Switching to triple-NRTI regimens in selected HIV-infected children with an extremely low likelihood of harbouring nucleoside-associated mutations maintains viral suppression and immunological function, improving metabolic abnormalities and the effort to take medication for up to 96 weeks.

Original languageEnglish
Pages (from-to)2465-2472
Number of pages8
JournalAIDS (London, England)
Volume21
Issue number18
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Highly Active Antiretroviral Therapy
Protease Inhibitors
Nucleosides
Reverse Transcriptase Inhibitors
HIV
Didanosine
Lipodystrophy
Lamivudine
Zidovudine
Dyslipidemias
T-Cell Antigen Receptor
Viral Load
RNA
T-Lymphocytes
Mutation

Keywords

  • CD8 T lymphocytes
  • HAART
  • HIV-1 infected children
  • Simplification
  • T cell Vβ

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. / Palma, Paolo; Romiti, Maria Luisa; Cancrini, Caterina; Pensieroso, Simone; Montesano, Carla; Santucci, Marilina B.; Bernardi, Stefania; Martino, Alessandra M.; Rossi, Paolo; Castelli-Gattinara, Guido.

In: AIDS (London, England), Vol. 21, No. 18, 12.2007, p. 2465-2472.

Research output: Contribution to journalArticle

Palma, Paolo ; Romiti, Maria Luisa ; Cancrini, Caterina ; Pensieroso, Simone ; Montesano, Carla ; Santucci, Marilina B. ; Bernardi, Stefania ; Martino, Alessandra M. ; Rossi, Paolo ; Castelli-Gattinara, Guido. / Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV. In: AIDS (London, England). 2007 ; Vol. 21, No. 18. pp. 2465-2472.
@article{7962d151d8fe4283932f4401c85f907c,
title = "Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV",
abstract = "OBJECTIVE: To assess the virological, immunological and metabolic effects of switching from an efficacious first-line protease inhibitor (PI)-based HAART to a simplified triple nucleoside reverse transcriptase inhibitor (NRTI) regimen in children vertically infected with HIV. DESIGN: Prospective, open-label, before-after study of 20 vertically infected children with at least 12 consecutive months of undetectable viral load under a PI-based HAART and no previous history of NRTI treatment. METHODS: At study entry, HAART was shifted to a triple-NRTI combination. RESULTS: The children were aged 2 to 18 years (median, 7.9) and were followed for 96 weeks. All were receiving a PI-based regimen for an average duration of 4 years before enrollment. At study entry, 12 patients (60{\%}) switched to abacavir, 5 (25{\%}) to lamivudine; 2 (10{\%}) to zidovudine and 2 to didanosine (10{\%}). All but one patient maintained plasma HIV RNA <50 copies/ml during the entire follow-up. No immunological failure was observed at week 96. A trend of normalization (P <0.001) of T cell receptor Vβ families of the CD8 cell subset was detected in 19/20 (95{\%}), with an increased HIV-specific CD8 T cell response (P <0.01) in 17/20 (85{\%}). Dyslipidaemia significantly improved during the follow up (P <0.001). No new cases of lipodystrophy were detected. CONCLUSIONS: Switching to triple-NRTI regimens in selected HIV-infected children with an extremely low likelihood of harbouring nucleoside-associated mutations maintains viral suppression and immunological function, improving metabolic abnormalities and the effort to take medication for up to 96 weeks.",
keywords = "CD8 T lymphocytes, HAART, HIV-1 infected children, Simplification, T cell Vβ",
author = "Paolo Palma and Romiti, {Maria Luisa} and Caterina Cancrini and Simone Pensieroso and Carla Montesano and Santucci, {Marilina B.} and Stefania Bernardi and Martino, {Alessandra M.} and Paolo Rossi and Guido Castelli-Gattinara",
year = "2007",
month = "12",
doi = "10.1097/QAD.0b013e3282f1560b",
language = "English",
volume = "21",
pages = "2465--2472",
journal = "AIDS",
issn = "0269-9370",
publisher = "NLM (Medline)",
number = "18",

}

TY - JOUR

T1 - Successful simplification of protease inhibitor-based HAART with triple nucleoside regimens in children vertically infected with HIV

AU - Palma, Paolo

AU - Romiti, Maria Luisa

AU - Cancrini, Caterina

AU - Pensieroso, Simone

AU - Montesano, Carla

AU - Santucci, Marilina B.

AU - Bernardi, Stefania

AU - Martino, Alessandra M.

AU - Rossi, Paolo

AU - Castelli-Gattinara, Guido

PY - 2007/12

Y1 - 2007/12

N2 - OBJECTIVE: To assess the virological, immunological and metabolic effects of switching from an efficacious first-line protease inhibitor (PI)-based HAART to a simplified triple nucleoside reverse transcriptase inhibitor (NRTI) regimen in children vertically infected with HIV. DESIGN: Prospective, open-label, before-after study of 20 vertically infected children with at least 12 consecutive months of undetectable viral load under a PI-based HAART and no previous history of NRTI treatment. METHODS: At study entry, HAART was shifted to a triple-NRTI combination. RESULTS: The children were aged 2 to 18 years (median, 7.9) and were followed for 96 weeks. All were receiving a PI-based regimen for an average duration of 4 years before enrollment. At study entry, 12 patients (60%) switched to abacavir, 5 (25%) to lamivudine; 2 (10%) to zidovudine and 2 to didanosine (10%). All but one patient maintained plasma HIV RNA <50 copies/ml during the entire follow-up. No immunological failure was observed at week 96. A trend of normalization (P <0.001) of T cell receptor Vβ families of the CD8 cell subset was detected in 19/20 (95%), with an increased HIV-specific CD8 T cell response (P <0.01) in 17/20 (85%). Dyslipidaemia significantly improved during the follow up (P <0.001). No new cases of lipodystrophy were detected. CONCLUSIONS: Switching to triple-NRTI regimens in selected HIV-infected children with an extremely low likelihood of harbouring nucleoside-associated mutations maintains viral suppression and immunological function, improving metabolic abnormalities and the effort to take medication for up to 96 weeks.

AB - OBJECTIVE: To assess the virological, immunological and metabolic effects of switching from an efficacious first-line protease inhibitor (PI)-based HAART to a simplified triple nucleoside reverse transcriptase inhibitor (NRTI) regimen in children vertically infected with HIV. DESIGN: Prospective, open-label, before-after study of 20 vertically infected children with at least 12 consecutive months of undetectable viral load under a PI-based HAART and no previous history of NRTI treatment. METHODS: At study entry, HAART was shifted to a triple-NRTI combination. RESULTS: The children were aged 2 to 18 years (median, 7.9) and were followed for 96 weeks. All were receiving a PI-based regimen for an average duration of 4 years before enrollment. At study entry, 12 patients (60%) switched to abacavir, 5 (25%) to lamivudine; 2 (10%) to zidovudine and 2 to didanosine (10%). All but one patient maintained plasma HIV RNA <50 copies/ml during the entire follow-up. No immunological failure was observed at week 96. A trend of normalization (P <0.001) of T cell receptor Vβ families of the CD8 cell subset was detected in 19/20 (95%), with an increased HIV-specific CD8 T cell response (P <0.01) in 17/20 (85%). Dyslipidaemia significantly improved during the follow up (P <0.001). No new cases of lipodystrophy were detected. CONCLUSIONS: Switching to triple-NRTI regimens in selected HIV-infected children with an extremely low likelihood of harbouring nucleoside-associated mutations maintains viral suppression and immunological function, improving metabolic abnormalities and the effort to take medication for up to 96 weeks.

KW - CD8 T lymphocytes

KW - HAART

KW - HIV-1 infected children

KW - Simplification

KW - T cell Vβ

UR - http://www.scopus.com/inward/record.url?scp=36348957298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348957298&partnerID=8YFLogxK

U2 - 10.1097/QAD.0b013e3282f1560b

DO - 10.1097/QAD.0b013e3282f1560b

M3 - Article

C2 - 18025883

AN - SCOPUS:36348957298

VL - 21

SP - 2465

EP - 2472

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 18

ER -